Total : 1 View more »
Savient Pharmaceuticals to Hold Third Quarter 2009 Financial Results Conference Call on Thursday, November 5, 2009.
Total : 22 View more »
EAST BRUNSWICK, N.J., Oct 27, 2009 (GlobeNewswire via COMTEX) --
Savient Pharmaceuticals, Inc. (Nasdaq:SVNT) today announced that Paul Hamelin, President of Savient Pharmaceuticals will be presenting at the upcoming Oppenheimer 20th Annual Healthcare Conference on November 3rd, 2009.
The presentation is scheduled to begin on Tuesday, November 3, 2009 at 1:35 p.m. Eastern Time. The conference will be held at The Waldorf Astoria in New York, NY, November 3-4, 2009.
Individuals can listen to a live webcast of the presentation by logging on to the Investor Relations section of Savient Pharmaceuticals' Web site at http://www.savient.com. A replay of the webcast will be available on the Company's Web site for 30 days.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA(TM) (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.
SVNT - G
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Savient Pharmaceuticals Inc
CONTACT: Savient Pharmaceuticals, Inc. Mary Coleman (732) 418-9300 information@savient.com Burns McClellan Susan Neath (212) 213-0006 sneath@burnsmc.com
Tags: conference manufacturer nasdaq new_york pharmaceuticals president university web
Companies: Savient Pharmaceuticals Inc (SVNT)
EAST BRUNSWICK, N.J., Oct 28, 2009 /PRNewswire via COMTEX/ --
EAST BRUNSWICK, N.J., Oct. 28 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the third quarter 2009 following the close of the market on Wednesday, November 4, 2009.
Paul Hamelin, President and David Gionco, Group Vice President and Chief Financial Officer, will host an investment community conference call beginning at 10:00 a.m. Eastern Time on November 5, 2009 to discuss these results and to answer questions.
To participate by telephone, please dial 888-397-5354 from the U.S. or 719-457-2615 for international callers. The conference identification number is 6621643. The live and archived webcast can be accessed on the investor relations section of the Savient Web site at www.savient.com. Please log on to Savient's Web site 15 minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.
A telephone replay will be available from 1:00 p.m. Eastern Time on November 5, 2009 through 11:59 p.m. Eastern Time on November 19, 2009 by dialing (888) 203-1112 (domestic) or (719) 457-0820 (international) and entering conference ID number 6621643.
About Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA(TM) (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.
SVNT-I
SOURCE Savient Pharmaceuticals, Inc.
http://www.savient.com
Tags: community conference financial results investment manufacturer nasdaq pharmaceuticals president university web
Companies: Savient Pharmaceuticals Inc (SVNT)
Oct 16, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --
Savient Pharmaceuticals, Inc., a US-based specialty biopharmaceutical company, has raised $65.72 million through a public offering of common stock. Including the over-allotment option which was exercised in full by the underwriters, the company sold a total of 4.945 million shares of its common stock at a price of $13.29 per share.
Update on October 8, 2009:
Savient has priced an underwritten public offering of 4.3 million shares of its common stock at a price of $13.29 per share.
In addition, Savient has granted the underwriters a 30-day option to purchase up to an additional 0.645 million shares of common stock to cover over-allotments.
The offering is expected to close on October 15, 2009.
Announcement (October 7, 2009):
Savient has filed a shelf registration statement with the US Securities and Exchange Commission (SEC) to issue 4 million shares of its common stock in an underwritten public offering.
Savient has granted the underwriters a 30 day option to purchase up to a 0.6 million additional shares of common stock to cover over-allotments, if any.
J.P. Morgan Securities, Inc. is acting as sole book-running manager, Wedbush PacGrow Life Sciences is acting as a lead manager and Lazard Capital Markets is acting as co-manager for the offering.
Deal Value (US$ Million) 65.72 Deal Type IPO Sub-Category Secondary Offering Deal Status Completed: 2009-10-15
Deal Participants
Target (Company) Savient Pharmaceuticals, Inc. (Formerly Bio-Technology General Corporation)
Deal Rationale
Savient will use the proceeds to seek FDA approval of KRYSTEXXA(T) (pegloticase), to develop a program of regulatory filings and review of KRYSTEXXA in other countries, to engage a global secondary source supplier and a secondary fill and finish manufacturer for pegloticase, and for working capital, and other general corporate purposes.
Offer Price ($ per share) 13.29 No. Shares Issued 4945000
Tags: book corporate fda ipo manufacturer pharmaceuticals public offering sec securities technology
EAST BRUNSWICK, N.J., Oct 15, 2009 /PRNewswire-FirstCall via COMTEX/ --
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 645,000 shares of common stock. As a result, Savient sold a total of 4,945,000 shares of its common stock at a price to the public of $13.29 per share. After underwriting discounts and commissions and estimated offering expenses, Savient received net proceeds of approximately $60.9 million. These shares were sold pursuant to Savient's existing shelf registration statement, the prospectus contained therein and the prospectus supplement as filed with the Securities Exchange Commission.
Savient intends to use the net proceeds from this offering to complete its effort to seek FDA approval of KRYSTEXXA(TM) (pegloticase), to develop a program of regulatory filings and review of KRYSTEXXA in other countries, to engage a global secondary source supplier and a secondary fill and finish manufacturer for pegloticase, and for working capital and other general corporate purposes.
J.P. Morgan Securities Inc. acted as sole book-running manager of the offering, with Wedbush PacGrow Life Sciences as lead manager and Lazard Capital Markets as co-manager. Copies of the final prospectus supplement and accompanying prospectus may be obtained by contacting J.P. Morgan Securities Inc., Attention: Prospectus Department, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA(TM) (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.
SVNT -G
SOURCE Savient Pharmaceuticals, Inc.
http://www.savient.com
Tags: book corporate exercise fda manufacturer nasdaq new_york pharmaceuticals public offering securities university
Companies: Savient Pharmaceuticals Inc (SVNT)
Total : 25 View more »
...EAST BRUNSWICK N.J. Nov. 4 /- Savient Pharmac... Our strengthened cash position will support future important initiati... Operational Key Events: During July 2009 we c...,Savient,Pharmaceuticals,Reports,Third,Quarter,2009,Financial,Results,medicine,advanced medical technology,medical laboratory
Copyright © 2002 - 2008 newratings.com GmbH | Legal | Licensing Quote data provided by IS.eFinance Solutions (powered by IS.Teledata AG) using StandardPoor's ComStock Inc. and others. Delay times are 15 mins for European exchanges and NASDAQ, 20 mins for NYSE and AMEX.
http://www.newratings.com/headlines/Savient-Pharmaceuticals-Inc-_US80517Q1004.html
EvaluatePharma provides historic and forecast sales from 1986 to 2010 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO.
Savient Pharmaceuticals thinks it has drug savvy. The company sold its global biologics manufacturing operations to private Swiss drugmaker Ferring to focus on new drug development. Those operations included Bio-Tropin, a growth hormone for children, and BioLon, a lubricant for ophthalmic surgery.
http://www.pharmacychoice.com/News/article.cfm?Article_ID=45555
Total : 44 View more »
Stay informed on the latest Savient Pharmaceuticals Incorporated news. TheStreet is the source for financial market and Wall Street news, trading stock and personal finance advice.
http://www.thestreet.com/topic/6042/savient-pharmaceuticals-incorporated.html
Find business news, business blogs, executive career advice, business travel, business culture, company & executive profiles.
http://www.portfolio.com/resources/company-profiles/Savient-Pharmaceuticals-Incorporated-1741
Get the latest SVNT - Savient Pharmaceuticals Incorporated stock market performance data. TheStreet is the source for financial market news, trading stock, quotes, and personal ...
Savient Pharmaceuticals Incorporated, East Brunswick, NJ : Reviews and maps - Yahoo! Local, 732.418.9300. Get Ratings, Reviews, Photos and more on Yahoo! Local.
http://local.yahoo.com/info-10990625-savient-pharmaceuticals-incorporated-east-brunswick